Tekla Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Tekla Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5,674	Closed	-$22.7M	–	171
2015 Q2	$22.7M	Hold	5,674	–	–	0.82%	25
2015 Q1	$22.7M	Buy	5,674 +3,398	+149%	+$15.6M	0.9%	24
2014 Q4	$11.2M	Hold	2,276	–	–	0.52%	45
2014 Q3	$9.26M	Buy	2,276 +395	+21%	+$1.48M	0.43%	46
2014 Q2	$7.61M	Buy	1,881 +940	+100%	+$3.83M	0.7%	40
2014 Q1	$4.28M	Hold	941	–	–	0.43%	44
2013 Q4	$3.3M	Hold	941	–	–	0.35%	46
2013 Q3	$3.87M	Hold	941	–	–	0.43%	47
2013 Q2	$3.72M	Buy	+941	New	+$3.87M	0.51%	45

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tekla Capital Management's ACOR Position: Q3 2015 in Review

Tekla Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2015, closing a stake of 5,674 shares — an estimated $22.7M sold.

Tekla Capital Management first reported a position in ACOR in Q2 2013 and held it in 9 quarters. The position peaked at $22.7M in Q2 2015. 176 funds tracked by Wall St. Rank hold ACOR as of Q3 2015.

Tekla Capital Management reported no remaining Acorda Therapeutics position as of Q3 2015 after selling out during the quarter.
Tekla Capital Management sold 5,674 Acorda Therapeutics shares in Q3 2015, an estimated $22.7M.
Tekla Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 9 quarters.
Tekla Capital Management's Acorda Therapeutics position peaked at $22.7M in Q2 2015.
176 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2015.

Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.